Skip to main content

Advertisement

SpringerLink
Log in

Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Burkitt’s lymphoma (BL) is an aggressive lymphoma sub-type with high 18F-FDG avidity, but no well established evidence of PET/CT’s role in treatment evaluation or prognosis is currently available. The prognostic role of visual analysis and Deauville criteria for BL have already been demonstrated, while the potential usefulness of semi-quantitative PET/CT features remains unclear, especially the value of the rate of reduction in metabolic tumor volume (MTV) and total lesion glycolysis (TLG). The aim of this retrospective study was to investigate whether ΔMTV and ΔTLG can predict treatment response at the end of therapy and prognosis in BL.

Methods

We retrospectively included 61 patients (mean age 61; 40 male, 21 female) who underwent baseline, interim and end-of-treatment 18F-FDG PET/CT. The PET/CT images were analyzed visually and semi-quantitatively by measuring total metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for every scan. Then we calculated volume changes based on the percentage of MTV and TLG reduction between the baseline and interim PET (ΔMTVi and ΔTLGi) and between baseline and end-of-treatment PET/CT (ΔMTVeot and ΔTLGeot) and correlated them with clinical response and progression-free survival (PFS) and overall survival (OS). Survival curves were plotted according to the Kaplan–Meier method.

Results

Forty patients had a complete response and 21 patients a partial response on interim 18F-FDG PET/CT. At end of treatment, 45 had a complete response, 11 partial response and 5 disease progression. At a median follow-up of 43 months, relapse/progression occurred in 18 patients and death in 11. ΔMTV and ΔTLG values were significantly higher in patients with complete response compared to no complete response. ΔMTVeot and ΔTLGeot were demonstrated to be independent prognostic factors for both PFS and OS, while ΔMTVi and ΔTLGi were not related to survival.

Conclusions

Metabolic tumor features (ΔMTV and ΔTLG) were significantly correlated with response to treatment and long-term outcome in BL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  2. Bishop PC, Rao VK, Wilson WH. Burkitt’s lymphoma: molecular pathogenesis and treatment. Cancer Invest. 2000;18:574–83.

    Article  CAS  PubMed  Google Scholar 

  3. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.

    Article  CAS  PubMed  Google Scholar 

  4. Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D’Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24:1879–86.

    Article  PubMed  Google Scholar 

  5. Molineux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt’s lymphoma. Lancet. 2012;379:1234–44.

    Article  Google Scholar 

  6. Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Hematol. 2012;156:761–5.

    Article  CAS  Google Scholar 

  7. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008;22:695–700.

    Article  PubMed  Google Scholar 

  8. Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R. Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med. 2009;4:355–8.

    Article  Google Scholar 

  9. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol. 2012;75:e68–73.

    Article  Google Scholar 

  10. Bailly C, Eugène T, Couec ML, Strullu M, Frampas E, Campion L, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne). 2014;16:1:54.

    Google Scholar 

  11. Carrillo-Cruz E,, Rodrıguez MS, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E, et al. Mar ın-Oyaga (?) VA. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol. 2015;94:23–30.

    Article  CAS  PubMed  Google Scholar 

  12. Wei WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ, et al. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer. 2015;2(34):608–13.

    Google Scholar 

  13. Albano D, Bosio G, Re A, Pagani C, Giubbini R, Bertagna F. Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma. 2018;3:1–8.

    Google Scholar 

  14. Albano D, Bosio G, Pagani C, Re A, Tucci A, Giubbini R, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:87–96.

    Article  PubMed  Google Scholar 

  15. Kostakoglu L, Chauvie S. Metabolic tumour volume metrics in lymphoma. Semin Nucl Med. 2018;48:50–66.

    Article  PubMed  Google Scholar 

  16. Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92:471–9.

    Article  CAS  PubMed  Google Scholar 

  17. Oñate-Ocaña LF, Cortés V, Castillo-Llanos R, Terrazas A, Garcia-Perez O, Pitalúa-Cortes Q, et al. Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. Oncol Lett. 2018;16:1411–8.

    PubMed  PubMed Central  Google Scholar 

  18. Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer J. 2015;5:e326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, et al. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    Article  CAS  PubMed  Google Scholar 

  22. Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024–34.

    Article  PubMed  Google Scholar 

  23. Albano D, Bosio G, Camoni L, Farina M, Re A, Tucci A, et al. Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol. 2018. https://doi.org/10.1002/hon.2563.

    Article  PubMed  Google Scholar 

  24. Moskowitz AJ, Schoder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130:2196–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.

    Article  CAS  PubMed  Google Scholar 

  26. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, et al. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med. 2018;32:532–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy

    Domenico Albano, Raffaele Giubbini & Francesco Bertagna

  2. Division of Hematology, Spedali Civili, Brescia, Italy

    Alessandro Re & Alessandra Tucci

Authors
  1. Domenico Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Re
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Tucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaele Giubbini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Albano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participant included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albano, D., Re, A., Tucci, A. et al. Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma. Ann Nucl Med 33, 280–287 (2019). https://doi.org/10.1007/s12149-019-01338-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-019-01338-9

Keywords

Search

Navigation